NCT07879339Not yet recruiting
Multi-omics Study of Cervical Neuroendocrine Carcinoma
A Real-World Retrospective Multi-Omics Study of Cervical Neuroendocrine Carcinoma
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
This is a retrospective study using archived tumor tissue and medical records from patients with cervical neuroendocrine carcinoma treated at Peking Union Medical College Hospital since January 1, 2015. Cervical neuroendocrine carcinoma is a rare and highly aggressive cervical cancer with no standard treatment. The study will analyze the tumor's genes, RNA, proteins, and immune environment to better understand its molecular features, identify molecular subtypes, find markers related to survival and immunotherapy, and build a prognostic prediction model. No new patients will be enrolled, and no additional tests or treatments will be given. About 80-120 patients are expected to be included. Results may help improve future diagnosis and personalized treatment for this rare cancer.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 10 Oct 2026
- Start date
- Nov 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Neuroendocrine tumours, Cervical cancer
- NCT number
- NCT07879339
What you commit to
- Study type: Observational
- Planned participants: 120
- From Nov 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 1: Failure to meet all of the above inclusion criteria
- 2: Archived tumor tissue specimens of inadequate quality for multi-omics testing
- 3: Severely missing key clinical data that preclude the extraction of valid information
- 4: Concomitant other malignancies (excluding non-melanoma skin cancer)
Who the study is looking for
- 1: Inclusion criteria Age ≥ 18 years
- 2: Histopathologically confirmed neuroendocrine carcinoma of the cervix (including small cell type, large cell type, and mixed type), reviewed and confirmed by at least two pathologists
- 3: Sufficient quality and quantity of archived tumor tissue specimens available for multi-omics testing (formalin-fixed paraffin-embedded tissue sections ≥ 10 slides or fresh frozen tissue ≥ 50 mg)
- 4: Complete clinical medical records and follow-up data (including at least diagnostic information, treatment regimen, and survival follow-up)
Age in the registry: 18 years to 100 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.